Transthyretin Amyloidosis Treatment Market Size, Share, Growth, and Industry Analysis, By Type (ATTR-PN, ATTR-CM), By Application (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies), Regional Insights and Forecast to 2035

Transthyretin Amyloidosis Treatment Market Overview

The global Transthyretin Amyloidosis Treatment Market size estimated at USD 5860.25 million in 2026 and is projected to reach USD 11813.35 million by 2035, growing at a CAGR of 8.11% from 2026 to 2035.

The Transthyretin Amyloidosis Treatment Market is expanding due to increased diagnosis of transthyretin amyloidosis (ATTR), wider genetic testing adoption, and the availability of disease-modifying therapies. ATTR amyloidosis affects the heart, peripheral nerves, and other organs through abnormal transthyretin protein deposition. Recent epidemiological assessments identified 59.8 prevalent ATTR cases per million people under narrow diagnostic criteria in the United States, while incidence reached 16.6 cases per million people. ATTR cardiomyopathy (ATTR-CM) represents the dominant treatment segment, accounting for 41.1 prevalent cases per million people. The market includes transthyretin stabilizers, RNA interference therapies, and antisense oligonucleotide therapies, with more than 20 active clinical programs supporting future treatment expansion.

The United States remains the largest individual market for transthyretin amyloidosis treatment due to strong diagnostic infrastructure and high disease awareness. In 2022, ATTR-CM incidence reached 12.7 cases per million people, while prevalence reached 41.1 cases per million people. Registry studies documented 390 ATTR patients across specialized centers, with 50.5% presenting wild-type disease. Male patients represented 85.4% of documented U.S. cases, and the average age of diagnosis exceeded 70 years in major registries. More than 34 transthyretin gene mutations have been identified in the U.S. population, supporting demand for precision diagnostics and targeted therapeutic interventions.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 68% of newly diagnosed ATTR-CM patients are identified through advanced imaging pathways, while diagnosis rates have improved by 42% in specialized cardiac centers, supporting higher treatment adoption.
• Major Market Restraint: Approximately 37% of patients experience diagnosis delays exceeding 24 months, while nearly 29% remain undiagnosed during early disease stages, restricting treatment penetration.
• Emerging Trends: RNA-based therapies account for 31% of ongoing late-stage development programs, while genetic screening utilization has increased by 46% among high-risk populations.
• Regional Leadership: North America holds approximately 44% of global treatment demand, supported by diagnosis rates exceeding 52% among suspected ATTR cardiomyopathy cases.
• Competitive Landscape: The top five manufacturers collectively control nearly 78% of approved treatment availability, while branded therapies account for approximately 92% of treated patient volumes.
• Market Segmentation: ATTR-CM therapies represent nearly 71% of total treatment utilization, while ATTR-PN therapies account for approximately 29% of treated cases worldwide.
• Recent Development: Clinical trial enrollment for next-generation ATTR therapies increased by 34%, while regulatory approvals for expanded indications rose by 22% during the recent development cycle.

Transthyretin Amyloidosis Treatment Market Latest Trends

The Transthyretin Amyloidosis Treatment Market is witnessing significant transformation through the expansion of RNA-targeted therapies and transthyretin stabilizers. RNA interference therapies have gained substantial attention due to their ability to reduce transthyretin protein production directly at the source. Recent Phase III studies demonstrated up to 36% reduction in all-cause mortality among ATTR-CM patients treated with advanced RNA-based therapies, highlighting the clinical value of gene-silencing approaches. Another important trend involves earlier diagnosis through cardiac imaging technologies. Nuclear scintigraphy, cardiac magnetic resonance imaging, and genetic testing are increasingly utilized to identify disease before advanced cardiac damage develops. Clinical studies show that diagnosis rates have improved significantly among patients older than 60 years, a demographic that represents the majority of ATTR-CM cases.

Pipeline diversification is also reshaping the market. More than 20 clinical programs are currently investigating novel ATTR treatments, including next-generation RNA interference molecules, antisense oligonucleotides, and transthyretin stabilizers. The market now includes approved therapies targeting both cardiomyopathy and polyneuropathy manifestations, improving treatment accessibility across patient populations. Another trend involves expanding treatment eligibility. Regulatory approvals between 2024 and 2025 broadened access to therapies for hereditary and wild-type ATTR-CM populations. Quarterly dosing schedules have improved patient compliance, while genetic testing utilization increased among families with hereditary disease risk. These developments are creating a more structured treatment pathway for a disease that historically suffered from delayed diagnosis and limited therapeutic options.

Transthyretin Amyloidosis Treatment Market Dynamics

DRIVER

"Rising diagnosis of transthyretin amyloidosis through advanced cardiac imaging and genetic testing."

The primary growth driver in the Transthyretin Amyloidosis Treatment Market is the increasing identification of ATTR patients through improved diagnostic technologies. In the United States, ATTR prevalence reached 59.8 cases per million people under narrow diagnostic definitions, while broader definitions identified 250.8 cases per million people. ATTR-CM accounts for the largest patient population, creating substantial demand for targeted therapies. Cardiac imaging technologies such as nuclear scintigraphy and MRI have significantly improved detection rates among patients older than 60 years. Genetic testing has also expanded identification of hereditary variants, including more than 34 documented mutations in U.S. registries. Earlier diagnosis enables faster therapeutic intervention, increasing utilization of transthyretin stabilizers and RNA-targeted treatments.

RESTRAINT

"Delayed diagnosis and limited disease awareness in community healthcare settings."

Despite therapeutic advancements, delayed diagnosis remains a major market restraint. ATTR-CM symptoms often resemble heart failure, hypertensive heart disease, and other cardiovascular conditions, resulting in frequent misclassification. Untreated ATTR-CM patients historically experienced survival periods of only 2 to 6 years after symptom progression. Many patients undergo multiple specialist consultations before receiving definitive diagnosis. Wild-type ATTR particularly affects older men above 70 years of age, a population frequently presenting with overlapping cardiovascular disorders. Additionally, specialized diagnostic equipment and expert interpretation remain concentrated in major treatment centers, limiting access for patients in smaller healthcare systems. These factors continue to reduce early treatment initiation rates despite growing awareness.

OPPORTUNITY

"Expansion of RNA interference and gene-silencing therapies."

The development of RNA-targeted therapeutics presents substantial opportunities for market expansion. Gene-silencing treatments directly reduce transthyretin protein production and have demonstrated meaningful clinical benefits. One major Phase III study reported up to 36% reduction in mortality outcomes among ATTR-CM patients. Several late-stage clinical programs are evaluating additional RNA interference molecules, antisense oligonucleotides, and combination therapies. More than 20 active development programs are currently focused on rare disease applications, including ATTR amyloidosis. Expansion into hereditary and wild-type patient populations increases addressable treatment demand. Longer dosing intervals, including four-dose annual schedules, further enhance patient convenience and adherence, supporting broader clinical adoption.

CHALLENGE

"High clinical complexity and patient heterogeneity."

ATTR amyloidosis presents substantial clinical challenges because patients may exhibit cardiomyopathy, polyneuropathy, or mixed disease manifestations. In the United States, prevalence estimates show 41.1 ATTR-CM cases per million people, 15.1 ATTR-PN cases per million people, and 9.8 mixed phenotype cases per million people. These diverse manifestations require individualized treatment approaches and multidisciplinary management teams. Furthermore, disease progression differs between hereditary and wild-type forms, complicating treatment selection and outcome evaluation. Clinical trials must recruit highly specific patient populations, extending development timelines. The rarity of the disease also limits patient availability for research studies, creating additional barriers for emerging therapeutic developers.

Transthyretin Amyloidosis Treatment Market Segmentation

Download FREE Sample to learn more about this report.

The Transthyretin Amyloidosis Treatment Market is segmented by type into ATTR-PN and ATTR-CM and by application into hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies. ATTR-CM represents the largest segment with approximately 71% treatment utilization due to higher prevalence among aging populations. ATTR-PN contributes approximately 29% of treatment demand because of hereditary disease burden. Hospital pharmacies account for the largest distribution share at approximately 46%, followed by specialty pharmacies at 33%. Retail pharmacies contribute 14%, while online pharmacies account for approximately 7% due to growing digital healthcare adoption and specialty drug delivery services.

BY TYPE

ATTR-PN: ATTR-PN remains a critical segment within the Transthyretin Amyloidosis Treatment Market due to hereditary transthyretin mutations affecting peripheral nerves. This segment accounts for approximately 29% of total treatment utilization. Epidemiological studies estimate 15.1 prevalent ATTR-PN cases per million people in the United States under narrow diagnostic criteria. Patients commonly experience sensory impairment, autonomic dysfunction, and progressive mobility limitations. RNA interference therapies and antisense oligonucleotide treatments dominate this segment because they target disease progression directly. Clinical adoption continues increasing due to enhanced genetic testing programs and family screening initiatives. More than 34 documented TTR mutations in U.S. registries support sustained demand for personalized treatment approaches and genetic counseling services.

ATTR-CM: ATTR-CM represents the dominant segment, accounting for approximately 71% of total treatment demand. U.S. prevalence reached 41.1 cases per million people, significantly exceeding ATTR-PN prevalence. Wild-type ATTR-CM primarily affects males older than 70 years, while hereditary forms contribute additional patient volume. Registry data indicate that 50.5% of documented U.S. ATTR cases involve wild-type disease. The segment benefits from expanding use of transthyretin stabilizers and RNA-targeted therapies. Cardiac imaging technologies have improved identification rates, supporting increased treatment initiation. Clinical evidence demonstrating mortality reduction and preservation of functional capacity further strengthens physician preference for disease-modifying therapies in ATTR-CM management.

BY APPLICATION

Hospital Pharmacies: Hospital pharmacies hold approximately 46% of market distribution share. Most newly diagnosed ATTR patients receive treatment initiation within tertiary care hospitals and specialized amyloidosis centers. Complex diagnostic workflows involving MRI, scintigraphy, and genetic testing are commonly performed within hospital networks. Hospital pharmacies also manage high-value specialty medicines requiring close monitoring and multidisciplinary physician oversight. Increasing referrals to specialized cardiac centers continue supporting strong hospital pharmacy demand.

Specialty Pharmacies: Specialty pharmacies account for approximately 33% of treatment distribution. These facilities play a crucial role in managing long-term administration of RNA-targeted therapies and transthyretin stabilizers. Specialty pharmacists provide adherence monitoring, patient education, and reimbursement support. Quarterly dosing schedules for several advanced therapies align effectively with specialty pharmacy service models. Growing use of chronic disease management programs is expanding this segment's importance.

Retail Pharmacies: Retail pharmacies contribute approximately 14% of market distribution. Oral transthyretin stabilizers are increasingly dispensed through retail pharmacy networks, improving patient convenience. Expansion of rare disease awareness programs has increased pharmacist involvement in patient counseling. Urban regions with high prescription volumes remain the primary contributors to retail pharmacy participation within the ATTR treatment ecosystem.

Online Pharmacies: Online pharmacies represent approximately 7% of treatment distribution. Digital healthcare adoption, home delivery services, and electronic prescription systems have improved patient access to maintenance therapies. Older patients managing chronic ATTR conditions increasingly utilize home-based medication delivery. Secure cold-chain logistics and telemedicine integration are supporting gradual expansion of this distribution channel.

Transthyretin Amyloidosis Treatment Market Regional Outlook

Download FREE Sample to learn more about this report.

North America leads the Transthyretin Amyloidosis Treatment Market through advanced diagnostics, strong clinical research infrastructure, and high treatment awareness. Europe follows with established rare disease frameworks and expanding access to innovative therapies. Asia-Pacific is experiencing rapid growth due to increasing diagnosis rates and healthcare modernization. Middle East & Africa remain emerging markets, supported by improving specialty care infrastructure and growing physician education initiatives focused on rare cardiovascular diseases.

NORTH AMERICA

North America accounts for approximately 44% of global Transthyretin Amyloidosis Treatment Market activity. The region benefits from advanced diagnostic capabilities, strong rare disease awareness, and widespread access to approved therapies. The United States represents the dominant contributor, with ATTR prevalence estimated at 59.8 cases per million people and incidence reaching 16.6 cases per million people. ATTR-CM prevalence alone reached 41.1 cases per million people, making cardiomyopathy the leading treatment category. Clinical research activity remains exceptionally strong across North America. More than 20 active development programs are evaluating novel therapies targeting transthyretin production and stabilization. Several regulatory approvals between 2024 and 2025 expanded treatment access for hereditary and wild-type ATTR patients. Genetic testing utilization continues increasing, particularly among high-risk populations carrying hereditary TTR mutations. The region also benefits from specialized amyloidosis centers, advanced cardiac imaging availability, and established reimbursement systems. Registry data show that male patients account for 85.4% of documented ATTR cases, while the average diagnosis age exceeds 70 years. These demographic characteristics support continued treatment demand as aging populations expand.

EUROPE

Europe accounts for approximately 29% of global market demand and maintains a strong position in transthyretin amyloidosis management. The region benefits from coordinated rare disease policies, advanced genetic screening programs, and extensive clinical trial participation. Several European countries have established referral networks dedicated to amyloidosis diagnosis and treatment. The adoption of RNA interference therapies accelerated following recent regulatory approvals supporting treatment of hereditary and wild-type ATTR-CM. Clinical studies demonstrated up to 36% mortality reduction among treated patients, strengthening physician confidence in advanced therapies. European treatment centers increasingly utilize nuclear imaging and cardiac MRI to identify disease at earlier stages. Countries including Germany, France, Italy, Spain, and the United Kingdom maintain active participation in ATTR clinical research. Registry programs support long-term patient monitoring and outcome assessment. Genetic screening initiatives are particularly important in regions with historically documented hereditary TTR mutations. Expanded specialist training programs have also improved disease recognition among cardiologists and neurologists. Access to orphan drug frameworks supports rapid adoption of innovative treatments. Growing awareness among healthcare professionals continues driving diagnosis rates, particularly for ATTR-CM, which remains the dominant indication across European healthcare systems.

ASIA-PACIFIC

Asia-Pacific represents approximately 19% of global treatment activity and is one of the fastest-evolving regions in the Transthyretin Amyloidosis Treatment Market. Japan remains a leading contributor due to longstanding recognition of hereditary ATTR disease and robust genetic testing infrastructure. Several Asian countries have increased investments in rare disease diagnostics and specialty treatment centers. The region benefits from a large aging population, particularly in Japan, South Korea, China, and Australia. Since wild-type ATTR-CM primarily affects individuals older than 60 years, demographic aging supports future patient identification. Improved access to cardiac imaging technologies has increased diagnostic accuracy across major urban healthcare facilities. Several countries have introduced national rare disease strategies that facilitate earlier diagnosis and improved treatment access. Growing healthcare expenditure, broader genetic testing adoption, and enhanced awareness among cardiologists and neurologists are expected to strengthen the region's position within the global ATTR treatment landscape.

MIDDLE EAST & AFRICA

Middle East & Africa account for approximately 8% of global market activity. Although the region currently represents the smallest share, significant opportunities exist through healthcare modernization and rare disease awareness initiatives. Major healthcare centers in the Gulf region increasingly incorporate advanced cardiac imaging and genetic testing capabilities. Government investments in precision medicine programs and genomic research are strengthening diagnostic infrastructure. Several tertiary hospitals now participate in international rare disease collaborations and patient registry programs. Access to advanced therapies remains concentrated in urban centers, but distribution networks continue expanding. Population aging trends across selected Middle Eastern countries are expected to increase identification of wild-type ATTR-CM. Growing awareness among healthcare providers and patients will likely improve referral patterns, supporting wider adoption of disease-modifying therapies throughout the forecast period.

List of Top Transthyretin Amyloidosis Treatment Companies

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Acrotech Biopharma
• AstraZeneca
• Astellas Pharma, Inc.
• Prothena
• SOM Biotech

List of Top 2 Companies Market Share

• Pfizer Inc.: approximately 39% market share driven by transthyretin stabilizer leadership and extensive cardiomyopathy treatment adoption.
• Alnylam Pharmaceuticals, Inc.: approximately 27% market share supported by RNA interference therapies and expanded approvals across ATTR-PN and ATTR-CM indications.

Investment Analysis and Opportunities

Investment activity within the Transthyretin Amyloidosis Treatment Market is concentrated around RNA interference technology, gene-silencing platforms, and next-generation transthyretin stabilizers. More than 20 active clinical programs are currently evaluating novel therapies targeting ATTR disease pathways. Pharmaceutical companies continue allocating substantial resources toward Phase II and Phase III studies focused on cardiomyopathy and polyneuropathy populations. ATTR prevalence estimates of 59.8 cases per million people and incidence of 16.6 cases per million people demonstrate an identifiable patient population requiring long-term therapy. Increasing diagnosis rates create opportunities for manufacturers, diagnostic developers, and specialty healthcare providers.

Investment opportunities are strongest in genetic testing technologies, AI-assisted cardiac imaging analysis, and precision medicine platforms. Clinical evidence showing up to 36% mortality reduction with advanced therapies strengthens investor confidence in disease-modifying treatment approaches. Additional opportunities exist in emerging markets where ATTR remains underdiagnosed. Expansion of specialty pharmacy networks, patient support services, and telemedicine programs can improve treatment access. Strategic partnerships between biotechnology companies and academic institutions continue accelerating innovation across diagnostics and therapeutic development.

New Product Development

New product development within the Transthyretin Amyloidosis Treatment Market focuses on improving efficacy, reducing dosing frequency, and expanding treatment eligibility. RNA interference therapies represent a major innovation category, directly suppressing transthyretin production at the genetic level. Recent approvals have expanded indications to include both hereditary and wild-type ATTR-CM populations. Several development programs are investigating next-generation RNA molecules with enhanced durability and simplified administration schedules. Quarterly dosing regimens have emerged as an important advancement, improving treatment adherence and reducing healthcare utilization. One approved therapy utilizes only four doses annually.

Transthyretin stabilizer innovation also continues. Two major stabilizers currently hold approval status, while additional compounds are being evaluated for improved protein stabilization and disease control. Gene-editing technologies represent another area of research. Early-stage programs aim to provide durable suppression of transthyretin production through one-time therapeutic interventions. Combined with advances in biomarker monitoring and precision diagnostics, these developments are expected to broaden treatment options for ATTR-CM and ATTR-PN patients.

Five Recent Developments

• In March 2025, the U.S. FDA expanded approval of Amvuttra for ATTR-CM, creating the first therapy approved for both polyneuropathy and cardiomyopathy manifestations.
• In June 2025, the European Commission approved Amvuttra for wild-type and hereditary ATTR-CM based on Phase III HELIOS-B data demonstrating up to 36% reduction in all-cause mortality.
• During 2025, Alnylam initiated the TRITON-CM Phase III trial evaluating nucresiran for ATTR cardiomyopathy patients.
• In 2025, clinical development pipelines exceeded 20 active programs focused on ATTR-related rare disease indications.
• In 2025, regulatory expansion increased treatment access for both hereditary and wild-type ATTR populations through broader indication approvals and label updates.

Report Coverage of Transthyretin Amyloidosis Treatment Market

This report provides comprehensive coverage of the Transthyretin Amyloidosis Treatment Market across disease type, treatment category, application channel, competitive environment, and regional performance. The analysis evaluates ATTR-PN and ATTR-CM segments, with particular emphasis on cardiomyopathy due to its prevalence of 41.1 cases per million people compared with 15.1 cases per million people for polyneuropathy.

The report examines epidemiological trends, including incidence of 16.6 cases per million people and prevalence of 59.8 cases per million people in the United States under narrow diagnostic criteria. Detailed assessment of hereditary and wild-type disease forms is included, together with analysis of more than 34 documented TTR mutations identified within patient registries. Coverage extends to approved therapies, emerging pipeline products, RNA interference technologies, antisense oligonucleotide programs, and transthyretin stabilizers. More than 20 active development programs are evaluated to identify future innovation opportunities.